{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:22:01Z","timestamp":1772612521115,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.arcmed.2013.10.016","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T02:45:39Z","timestamp":1383878739000},"page":"633-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-Inflammatory Interventions in End-stage Kidney Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Alfonso M.","family":"Cueto-Manzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"\u00c1ngel-Z\u00fa\u00f1iga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabina","family":"Ornelas-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Rojas-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor R.","family":"Mart\u00ednez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cort\u00e9s-Sanabria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2013.10.016_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1523-1755.2001.059002407.x","article-title":"End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?","volume":"59","author":"Arici","year":"2001","journal-title":"Kidney Int"},{"issue":"suppl 11","key":"10.1016\/j.arcmed.2013.10.016_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_11.28","article-title":"The malnutrition, inflammation, and atherosclerosis (MIA) syndrome\u2014the heart of the matter","volume":"17","author":"Pecoits-Filho","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 80","key":"10.1016\/j.arcmed.2013.10.016_bib3","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1046\/j.1523-1755.61.s80.18.x","article-title":"Inflammation and cardiovascular risk in dialysis patients","volume":"61","author":"Wanner","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib4","unstructured":"The United States Renal Data System. Annual Data Report. 2012. http:\/\/www.usrds.org (15 July 2013 date last accessed)."},{"issue":"suppl 1","key":"10.1016\/j.arcmed.2013.10.016_bib5","doi-asserted-by":"crossref","first-page":"20A","DOI":"10.1016\/j.amjcard.2005.11.012","article-title":"Inflammation in renal disease","volume":"97","author":"Vidt","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arcmed.2013.10.016_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000330355","article-title":"The role of statins in chronic kidney disease","volume":"34","author":"Kalaitzidis","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.arcmed.2013.10.016_bib7","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"2","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcmed.2013.10.016_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2013.10.016_bib9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2013.10.016_bib10","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2013.10.016_bib11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.arcmed.2013.10.016_bib12","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ki.2008.484","article-title":"for the German Diabetes and Dialysis Study Investigators. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis","volume":"74","author":"Krane","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/ajkd.2002.33393","article-title":"Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients","volume":"39","author":"Chang","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.arcmed.2013.10.016_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/089686080602600311","article-title":"Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis?","volume":"26","author":"Cueto-Manzano","year":"2006","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/089686080102100207","article-title":"Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single center","volume":"21","author":"Cueto-Manzano","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib16","first-page":"184","article-title":"Patient and technique survival in continuous ambulatory peritoneal dialysis in a single center of the west of Mexico","volume":"59","author":"Rojas-Campos","year":"2007","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.arcmed.2013.10.016_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/089686080702700326","article-title":"Inflammation in peritoneal dialysis: a Latin American perspective","volume":"27","author":"Cueto-Manzano","year":"2007","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/089686080702700313","article-title":"Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients","volume":"27","author":"Kumar","year":"2007","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.arcmed.2013.10.016_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/00365590701517244","article-title":"Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients","volume":"41","author":"Sezer","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.arcmed.2013.10.016_bib20","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/bmj.316.7146.1719","article-title":"Understanding controlled trials. Crossover trials","volume":"316","author":"Sibbald","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.arcmed.2013.10.016_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2004.07.003","article-title":"Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients","volume":"177","author":"Ascer","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arcmed.2013.10.016_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","article-title":"Strong decrease of high sensitivity C-reactive protein with high dose atorvastatin in patients with type 2 diabetes mellitus","volume":"166","author":"van de Ree","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arcmed.2013.10.016_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.110.985150","article-title":"Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin mediated endothelial nitric oxide synthase coupling","volume":"124","author":"Antoniades","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2013.10.016_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0021-9150(99)00189-6","article-title":"HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease","volume":"147","author":"Jarvisalo","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arcmed.2013.10.016_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"21suppl 1","key":"10.1016\/j.arcmed.2013.10.016_bib26","first-page":"II18","article-title":"Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?","volume":"109","author":"Schonbeck","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2013.10.016_bib27","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","article-title":"Direct proinflammatory effect of C-reactive protein on human endothelial cells","volume":"102","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2013.10.016_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.0000029802.88087.5E","article-title":"A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis","volume":"106","author":"Verma","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2013.10.016_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.0000052617.91920.FD","article-title":"C-reactive protein increases plasminogen activator inhibitor\u20131 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis","volume":"107","author":"Devaraj","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2013.10.016_bib30","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440913002610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440913002610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:42:57Z","timestamp":1759261377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440913002610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0188440913002610"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2013.10.016","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Inflammatory Interventions in End-stage Kidney Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2013.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}